The future of targeted therapies for brain metastases.

Brain metastases (BM) are an increasing challenge in the management of patients with advanced cancer. Treatment options for BM are limited and mainly focus on the application of local therapies. Systemic therapies including targeted therapies are only poorly investigated, as patients with BM were frequently excluded from clinical trials. Several targeted therapies have shown promising activity in patients with BM. In the present review we discuss existing and emerging targeted therapies for the most frequent BM primary tumor types. We focus on challenges in the conduction of clinical trials on targeted therapies in BM patients such as patient selection, combination with radiotherapy, the obstacles of the blood-brain barrier and the definition of study end points.

[1]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Yamada,et al.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.

[3]  G. Nagaraj,et al.  Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer , 2015, Breast Cancer Research and Treatment.

[4]  Sean Khozin,et al.  FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[5]  Caicun Zhou,et al.  Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. , 2015, Clinical lung cancer.

[6]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[7]  R. Weil,et al.  Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. , 2015, Neuro-oncology.

[8]  J. Pichler,et al.  Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases , 2015, Neuropathology and applied neurobiology.

[9]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[10]  S. Margolin,et al.  CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Ricken,et al.  Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases , 2015, Histopathology.

[12]  J. Hainfellner,et al.  Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer , 2014, Histopathology.

[13]  K. Blackwell,et al.  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Brastianos,et al.  Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues , 2014, Acta Neuropathologica.

[15]  A. Shaw,et al.  1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[17]  B. Dréno,et al.  Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib , 2014, Journal of Neuro-Oncology.

[18]  J. O’Shaughnessy,et al.  BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. , 2014, Lung cancer.

[19]  D. Kondziolka,et al.  It is time to reevaluate the management of patients with brain metastases. , 2014, Neurosurgery.

[20]  A. Ferro,et al.  Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series. , 2014, Clinical genitourinary cancer.

[21]  Michael Thomas,et al.  Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. , 2014 .

[22]  P. Ascierto,et al.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.

[23]  M. Preusser,et al.  ROS1 translocations and amplifications in lung cancer brain metastases , 2014, Journal of Neuro-Oncology.

[24]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[25]  W. Wick,et al.  Microenvironmental Clues for Glioma Immunotherapy , 2014, Current Neurology and Neuroscience Reports.

[26]  H. Heinzl,et al.  Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases , 2014, Strahlentherapie und Onkologie.

[27]  A. Ravaud,et al.  A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. , 2014, Clinical genitourinary cancer.

[28]  R. Dummer,et al.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.

[29]  C. Rödel,et al.  Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib , 2014, Strahlentherapie und Onkologie.

[30]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[31]  Katherine W Ferrara,et al.  Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[32]  N. Lin,et al.  CNS Metastases in Breast Cancer: Old Challenge, New Frontiers , 2013, Clinical Cancer Research.

[33]  Yasuyoshi Watanabe,et al.  64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer , 2013, The Journal of Nuclear Medicine.

[34]  Myles A Brown,et al.  PET imaging of oestrogen receptors in patients with breast cancer. , 2013, The Lancet. Oncology.

[35]  T. Choueiri,et al.  Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. , 2013, Clinical genitourinary cancer.

[36]  Susan M. Chang,et al.  Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. , 2013, The Lancet. Oncology.

[37]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[38]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[39]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[40]  Erin M. Olson,et al.  Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  C. Bokemeyer,et al.  CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. , 2013, Lung cancer.

[42]  C. Marosi,et al.  ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. , 2013, Lung cancer.

[43]  Meihua Wang,et al.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. , 2013, International journal of radiation oncology, biology, physics.

[44]  J. Pichler,et al.  Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases , 2012, Clinical and Experimental Metastasis.

[45]  S. Vaidhyanathan,et al.  Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[46]  J. Brugarolas,et al.  Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Gelber,et al.  CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). , 2013, The Lancet. Oncology.

[48]  Joe Y. Chang,et al.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Daniela Prayer,et al.  Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times , 2013, PloS one.

[50]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[51]  M. Preusser,et al.  Optimal Management of Brain Metastases from Breast Cancer , 2013, CNS Drugs.

[52]  D. Schadendorf,et al.  Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. , 2012, European journal of cancer.

[53]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[54]  B. Neyns,et al.  Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. , 2012, European journal of cancer.

[55]  O. Chinot,et al.  Recent trends in epidemiology of brain metastases: an overview. , 2012, Anticancer research.

[56]  A. Hauschild,et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[57]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[58]  C. Marosi,et al.  Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors , 2012, British Journal of Cancer.

[59]  A. Niemierko,et al.  Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype , 2012, Breast Cancer Research and Treatment.

[60]  E. Winer,et al.  A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Wolchok How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  R. Dziadziuszko,et al.  Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain , 2012, Breast Cancer Research.

[63]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[64]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[65]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[66]  G. Ceresoli Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer. , 2012, Current cancer drug targets.

[67]  D. Fortin The blood-brain barrier: its influence in the treatment of brain tumors metastases. , 2012, Current cancer drug targets.

[68]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Pichler,et al.  Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases , 2012, Acta Neuropathologica.

[70]  M. Jamal-Hanjani,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain , 2011, Clinical Cancer Research.

[71]  M. Gnant,et al.  Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases , 2011, British Journal of Cancer.

[72]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[73]  P. Steeg,et al.  In Vivo Characterization of Changing Blood-Tumor Barrier Permeability in a Mouse Model of Breast Cancer Metastasis: A Complementary Magnetic Resonance Imaging Approach , 2011, Investigative radiology.

[74]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[75]  P. Hwu,et al.  Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.

[76]  C. Porta,et al.  Sunitinib in metastatic renal cell carcinoma patients with brain metastases , 2011, Cancer.

[77]  L. Sequist,et al.  EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. , 2010, Neuro-oncology.

[78]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[79]  B. Yeap,et al.  Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib , 2010, Clinical Cancer Research.

[80]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[81]  K. Harmankaya,et al.  Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma , 2010, BMC Cancer.

[82]  C. Szczylik,et al.  Incidence of brain metastases in renal cell carcinoma treated with sorafenib. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[84]  Sang-We Kim,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. , 2009, Lung cancer.

[85]  J. Shih,et al.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  G. Steger,et al.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer , 2007, Journal of Neuro-Oncology.

[87]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  E. Winer,et al.  Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.

[89]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[90]  P. Cornu,et al.  EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force , 2006, European journal of neurology.

[91]  R. Weil,et al.  Breast cancer metastasis to the central nervous system. , 2005, The American journal of pathology.

[92]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[93]  M. Dewhirst,et al.  The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. , 2005, AJR. American journal of roentgenology.

[94]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  F. Cappuzzo,et al.  Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[97]  Marco van Vulpen,et al.  Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). , 2002, Oncology reports.

[98]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[99]  H. Hansen,et al.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  L. Hollier,et al.  Review of 'It Is Time to Reevaluate the Management of Patients With Brain Metastases' by Kondziolka D, Kalkanis SN, Mehta MP, Ahluwalia M, Loeffler JS in Neurosurgery 75: 1–9, 2014 , 2015 .

[101]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[102]  D. Cahill,et al.  Systemic Therapy of Brain Metastases , 2014, Current Neurology and Neuroscience Reports.

[103]  W. Berger,et al.  High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. , 2014, Lung cancer.

[104]  D. Kondziolka,et al.  The accuracy of predicting survival in individual patients with cancer. , 2014, Journal of neurosurgery.

[105]  M. Preusser,et al.  Breast cancer brain metastases responding to primary systemic therapy with T-DM1 , 2013, Journal of Neuro-Oncology.

[106]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[107]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[108]  V. Perry,et al.  What is the blood-brain barrier (not)? , 2007, Trends in immunology.

[109]  T. Yoshimine,et al.  Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats , 2005, Acta Neurochirurgica.